Which has preferable earnings and valuation, COGT or DMRA?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A

Is COGT or DMRA more profitable?

Cogent Biosciences' return on equity of -104.27% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62%

Does the media refer more to COGT or DMRA?

In the previous week, Cogent Biosciences had 2 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for Cogent Biosciences and 4 mentions for Damora Therapeutics, Inc. Common Stock. Cogent Biosciences' average media sentiment score of 1.73 beat Damora Therapeutics, Inc. Common Stock's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive Damora Therapeutics, Inc. Common Stock 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor DMRA or CGON?

In the previous week, CG Oncology had 25 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 29 mentions for CG Oncology and 4 mentions for Damora Therapeutics, Inc. Common Stock. CG Oncology's average media sentiment score of 0.03 beat Damora Therapeutics, Inc. Common Stock's score of 0.00 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CG Oncology 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Is DMRA or XENE more profitable?

Xenon Pharmaceuticals' return on equity of -43.98% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62% Xenon Pharmaceuticals N/A -43.98% -41.72%

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

$29.54 -0.38 (-1.27%)

As of 04:00 PM Eastern

Compare

DMRA vs. COGT, MIRM, CGON, XENE, and LGND

Should you buy Damora Therapeutics, Inc. Common Stock stock or one of its competitors? Damora Therapeutics, Inc. Common Stock's main competitors and comparable companies include Cogent Biosciences (COGT), Mirum Pharmaceuticals (MIRM), CG Oncology (CGON), Xenon Pharmaceuticals (XENE), and Ligand Pharmaceuticals (LGND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. 6.6% of Cogent Biosciences shares are held by insiders. Comparatively, 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cogent Biosciences has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market.

Cogent Biosciences' return on equity of -104.27% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%

Cogent Biosciences is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A

In the previous week, Cogent Biosciences had 2 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 6 mentions for Cogent Biosciences and 4 mentions for Damora Therapeutics, Inc. Common Stock. Cogent Biosciences' average media sentiment score of 1.73 beat Damora Therapeutics, Inc. Common Stock's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cogent Biosciences currently has a consensus target price of $45.90, suggesting a potential upside of 10.52%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $44.00, suggesting a potential upside of 48.95%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92

Summary

Cogent Biosciences and Damora Therapeutics, Inc. Common Stock tied by winning 6 of the 12 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Mirum Pharmaceuticals?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

In the previous week, Mirum Pharmaceuticals had 31 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 35 mentions for Mirum Pharmaceuticals and 4 mentions for Damora Therapeutics, Inc. Common Stock. Mirum Pharmaceuticals' average media sentiment score of 0.11 beat Damora Therapeutics, Inc. Common Stock's score of 0.00 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $44.00, suggesting a potential upside of 48.95%. Mirum Pharmaceuticals has a consensus price target of $137.33, suggesting a potential upside of 39.14%. Given Damora Therapeutics, Inc. Common Stock's higher probable upside, equities research analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Mirum Pharmaceuticals has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Mirum Pharmaceuticals	$521.31M	12.29	-$23.36M	-$14.55	N/A

Damora Therapeutics, Inc. Common Stock has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Mirum Pharmaceuticals' return on equity of -36.28% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Mirum Pharmaceuticals	-139.18%	-36.28%	-8.54%

Summary

Mirum Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 9 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to CG Oncology?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, CG Oncology had 25 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 29 mentions for CG Oncology and 4 mentions for Damora Therapeutics, Inc. Common Stock. CG Oncology's average media sentiment score of 0.03 beat Damora Therapeutics, Inc. Common Stock's score of 0.00 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CG Oncology	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

14.2% of Damora Therapeutics, Inc. Common Stock shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

CG Oncology has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. CG Oncology is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
CG Oncology	$4.04M	1,679.77	-$160.99M	-$2.69	N/A

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $44.00, suggesting a potential upside of 48.95%. CG Oncology has a consensus price target of $83.18, suggesting a potential upside of 8.65%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher probable upside, equities research analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -26.58% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
CG Oncology	-3,602.68%	-26.58%	-25.34%

Summary

CG Oncology beats Damora Therapeutics, Inc. Common Stock on 10 of the 16 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Xenon Pharmaceuticals?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Xenon Pharmaceuticals' return on equity of -43.98% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

In the previous week, Xenon Pharmaceuticals had 11 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 15 mentions for Xenon Pharmaceuticals and 4 mentions for Damora Therapeutics, Inc. Common Stock. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat Damora Therapeutics, Inc. Common Stock's score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $44.00, suggesting a potential upside of 48.95%. Xenon Pharmaceuticals has a consensus target price of $77.13, suggesting a potential upside of 20.09%. Given Damora Therapeutics, Inc. Common Stock's higher probable upside, equities research analysts plainly believe Damora Therapeutics, Inc. Common Stock is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Damora Therapeutics, Inc. Common Stock has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Xenon Pharmaceuticals	$7.50M	827.88	-$345.91M	-$4.74	N/A

Damora Therapeutics, Inc. Common Stock has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Xenon Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.

How does Damora Therapeutics, Inc. Common Stock compare to Ligand Pharmaceuticals?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Damora Therapeutics, Inc. Common Stock has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market.

Ligand Pharmaceuticals has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Ligand Pharmaceuticals	$290.54M	20.40	$124.45M	$9.35	31.63

Ligand Pharmaceuticals has a net margin of 67.88% compared to Damora Therapeutics, Inc. Common Stock's net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Ligand Pharmaceuticals	67.88%	20.06%	11.68%

Damora Therapeutics, Inc. Common Stock currently has a consensus price target of $44.00, suggesting a potential upside of 48.95%. Ligand Pharmaceuticals has a consensus price target of $336.57, suggesting a potential upside of 13.82%. Given Damora Therapeutics, Inc. Common Stock's stronger consensus rating and higher possible upside, research analysts clearly believe Damora Therapeutics, Inc. Common Stock is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.92
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Ligand Pharmaceuticals had 23 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 27 mentions for Ligand Pharmaceuticals and 4 mentions for Damora Therapeutics, Inc. Common Stock. Ligand Pharmaceuticals' average media sentiment score of 0.57 beat Damora Therapeutics, Inc. Common Stock's score of 0.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ligand Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Ligand Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 11 of the 16 factors compared between the two stocks.

Get Damora Therapeutics, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMRA vs. The Competition

Export

Metric	Damora Therapeutics, Inc. Common Stock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.82B	$3.72B	$7.06B	$12.95B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-5.29	9.13	269.75	24.73
Price / Sales	N/A	1,274.20	652.34	108.63
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	-0.27	17.66	11.27	6.42
Net Income	-$209.84M	-$13.25M	$3.45B	$347.12M
7 Day Performance	3.43%	5.36%	3.56%	2.48%
1 Month Performance	3.54%	-1.74%	-0.58%	-1.04%
1 Year Performance	773.96%	61.36%	77.52%	23.22%

Damora Therapeutics, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMRA Damora Therapeutics, Inc. Common Stock	1.8096 of 5 stars	$29.54 -1.3%	$44.00 +49.0%	+785.2%	$1.82B	N/A	N/A	40	Earnings Report
COGT Cogent Biosciences	1.6945 of 5 stars	$42.84 +10.2%	$45.90 +7.1%	+286.8%	$6.64B	N/A	N/A	80	News Coverage Positive News Earnings Report Gap Down High Trading Volume
MIRM Mirum Pharmaceuticals	2.9442 of 5 stars	$104.33 -0.2%	$143.40 +37.4%	+67.8%	$6.38B	$521.31M	N/A	140	Positive News Earnings Report Analyst Upgrade Analyst Revision
CGON CG Oncology	2.2067 of 5 stars	$71.40 +3.3%	$81.73 +14.5%	+202.2%	$6.10B	$4.04M	N/A	61	Earnings Report Analyst Forecast Analyst Revision
XENE Xenon Pharmaceuticals	2.63 of 5 stars	$64.01 +2.8%	$77.20 +20.6%	+89.5%	$6.02B	$7.50M	N/A	210	Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMRA) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. COGT, MIRM, CGON, XENE, and LGND

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Mirum Pharmaceuticals?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to CG Oncology?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Xenon Pharmaceuticals?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Ligand Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Damora Therapeutics, Inc. Common Stock (DMRA) Competitors

DMRA vs. COGT, MIRM, CGON, XENE, and LGND

How does Damora Therapeutics, Inc. Common Stock compare to Cogent Biosciences?

Do insiders and institutionals hold more shares of COGT or DMRA?

Which has more volatility & risk, COGT or DMRA?

Is COGT or DMRA more profitable?

Which has preferable earnings and valuation, COGT or DMRA?

Does the media refer more to COGT or DMRA?

Do analysts recommend COGT or DMRA?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Mirum Pharmaceuticals?

Does the media refer more to DMRA or MIRM?

Do analysts prefer DMRA or MIRM?

Do insiders & institutionals have more ownership in DMRA or MIRM?

Which has preferable valuation & earnings, DMRA or MIRM?

Which has more risk & volatility, DMRA or MIRM?

Is DMRA or MIRM more profitable?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to CG Oncology?

Does the media favor DMRA or CGON?

Do insiders and institutionals hold more shares of DMRA or CGON?

Which has more volatility & risk, DMRA or CGON?

Which has stronger earnings and valuation, DMRA or CGON?

Do analysts recommend DMRA or CGON?

Is DMRA or CGON more profitable?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Xenon Pharmaceuticals?

Is DMRA or XENE more profitable?

Does the media favor DMRA or XENE?

Do analysts rate DMRA or XENE?

Which has stronger valuation & earnings, DMRA or XENE?

Which has more risk & volatility, DMRA or XENE?

Do insiders & institutionals hold more shares of DMRA or XENE?

Summary

How does Damora Therapeutics, Inc. Common Stock compare to Ligand Pharmaceuticals?

Which has more risk and volatility, DMRA or LGND?

Which has higher earnings and valuation, DMRA or LGND?

Is DMRA or LGND more profitable?

Do analysts rate DMRA or LGND?

Does the media favor DMRA or LGND?

Do institutionals and insiders hold more shares of DMRA or LGND?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMRA vs. The Competition

Damora Therapeutics, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools